A long term follow up of people who already received AAVAnc80-antiVEGF gene therapy for a vestibular schwannoma
Official title: Long Term Follow-up Study of AAVAnc80-antiVEGF Gene Therapy
Status: Enrolling by invitation. It is only taking people the trial team invites. You cannot sign up for this one directly.
The trial team last updated this record on .
The short version
This study keeps track of how people do over time after they got a gene therapy called AAVAnc80-antiVEGF.
Read our full plain-language summary
What the trial team says
This multi-center, observational, post-intervention LTFU study will monitor for safety and efficacy of AAVAnc80- antiVEGF in individuals with vestibular schwannoma who have previously received an intracochlear administration of AAVAnc80-antiVEGF in an interventional clinical trial
Key facts
- Registry number
- NCT07503613
- Conditions studied
- Vestibular Schwannoma
Where it is running
This trial lists 1 site.
-
Texas
- University of Texas Southwestern (Dallas)
How to use this
Talk to your care team first. They know your history and can tell you whether this trial is worth your time.
Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.
This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.